VEWD
14.10.2021 14:50:07 CEST | Business Wire | Press release
Vewd , the leading provider of OTT software solutions, together with Vestel, Europe’s largest TV manufacturer, today introduced the Vewd Operator TV, a fully-featured Smart TV with a built-in, content-enriched Pay TV experience. Now, Pay TV Operators can win the retail Smart TV landscape.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211014005674/en/
Rather than up-selling Pay TV services through a separate set-top box or competing alongside other apps inside hard-to-discover Smart TV app environments, operators can now own the entire Smart TV consumer experience – from home screen to app discoverability – from the moment a consumer purchases the TV.
Operator TV combines Vewd’s industry-leading Smart TV software with Vestel’s TV manufacturing, warehousing and distribution expertise. Vestel produces TV’s for more than 100 of the world’s iconic brands, including JVC, Hitachi, Telefunken, and Toshiba. Operators not only benefit from having a leading manufacturer for their own or co-branded televisions, but also can rely upon Vestel’s robust logistics capabilities to ensure simplified procurement, warehousing and delivery of their Operator TV.
“Vestel is pleased to add our expertise in building high-quality, full-featured Smart TVs to empower Vewd’s Operator TV solution,” said Barış Altınkaya, Vestel Vice President of Marketing and Product Management. “By working directly with Vewd and the Operator, we can leverage our vast manufacturing and retail distribution experience to contribute in reducing time-to-market, enabling substantial Operator CapEx savings while delivering an experience that delights subscribers, reduces churn and improves subscriber satisfaction.”
Vewd’s Software-as-a-Service (SaaS) business model aligns Operator TV with Pay TV subscription models and revenue, distributing costs, development time and risk. Critical functionality comes standard in an Operator TV:
- Conditional Access available to ensure broadcast and IP content security
- Cloud-managed reference user experience (UX) or the Operator’s customized UI
- Content including premium OTT and video-on-demand, FAST channels and full support for broadcast channels
“Operators have tried different strategies to embrace Smart TV, but together with Vestel, we've made the first solution that seamlessly connects Pay TV and Smart TV,” said Aneesh Rajaram, CEO of Vewd. “Consumers are streaming more and connecting fewer devices to the TV. As a result, Operators are forced to fight for visibility among Smart TV apps. Vewd Operator TV ensures Operators of any size can seize control from the start and win the home’s most important screen.”
Vewd's Operator TV solution is enabled via Vewd’s white-labeled product suite which includes Vewd OS . Visit our website to learn more about the benefits of Operator TV .
About Vewd
Vewd is the leading provider of OTT and hybrid TV solutions, connecting consumers anywhere to the content they love. By making OTT possible on almost 40 million connected devices each year, Vewd leads the way in defining the future of entertainment. Our suite of products and services are crafted to simplify complexity and offer solutions that unite the entire value chain, from silicon vendors to end-users. Market leaders such as Sony, Hisense, TPV, Vodafone, Sagemcom, and many more rely on Vewd products and services. Follow us, as we make TV connected. Visit Vewd.com to learn more.
About Vestel
Comprised of 28 companies, Vestel Group is a multi-industry manufacturer that operates in consumer electronics, home appliances, professional displays, LED lighting, and EV Chargers. Testimony to the global importance of Zorlu Holding across multiple technology sectors, Vestel is not only thriving at home in Turkey, but also through a further 10 subsidiaries that have been set up in various other parts of the world. Thanks to its renowned manufacturing and R&D complex, Vestel exports to 157 countries and keeps its position as a global player. More information: vestelinternational.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014005674/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom